At GrittGene Therapeutics, we combine preparatory, targeted tissue delivery of CRISPR gene editing system with AI-based patient-specific genome screening to significantly increase CRISPR gene editing efficiency and radically reduce off-target integration.
It is simple, the cure is the goal, we don’t just cover symptoms.
At GrittGene Therapeutics, our Mission is to cure patients with Myotonic Dystrophy Type 2. We develop the cure of tomorrow by combining all the tools available today. With our disease-centric
approach, with the cure being the main driving force, GrittGene’s
interdisciplinary platform is free from the constraints of big pharma. In our hands, alleviation of disease symptoms is just an observable effect of the cure. The collaborative environment at GrittGene combines the power of expert scientists from various branches of pharmaceutical industries and more. We employ
cutting-edge technologies including CRISPR and Artificial
Intelligence for tissue-specific delivery and gene-specific
editing, a combination of small-molecule treatment with biologicals and gene therapy. We are not limited by internal
technology; we are free to develop treatment the right way through collaboration and a combination of the complete pool
of technologies and wealth of knowledge at our disposal today.
capacity to use a wide range of expertise and experiences in diverse aspects of
drug discovery and beyond, we believe that
effective use of all possible tools will lead us to
Provide collaborative platform where the accumulated Knowledge, Experience, Relationships, Networks & Partnerships will come together to accomplish our mission.
DM patients are our priority, without compromise.
We are not money driven.
We don't compete with
who seek a
solution for DM.
We partner with them to accelerate the development of the Cure.